In a clinical trial to assess the adoptive transfer of short-term IL-2 activated NK cells in treating patients with AML and high-risk MDS performed at Karolinska University Hospital, patients who received NK cells with higher endogenous expression of the BM homing receptor CXCR4 had a higher likelihood of responding compared to those receiving a product with lower cell surface levels of endogenous CXCR43. The gene discussed is IL2; the disease is acute myeloid leukemia.